Ren Jinsheng's Form 4 filing
NextCure, Inc. (NXTC) · filed Aug 12, 2026
- Accession no.
- 0001213900-26-088156
- Filed
- Aug 12, 2026, 11:35 AM ET
- Trade date
- Aug 10, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $184.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ren JinshengCIK 0001455397 | Other: Former 10% Owner |
| Simcere Zaiming, Inc.CIK 0002080252 | Other: Former 10% Owner |
| Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.CIK 0002082506 | Other: Former 10% Owner |
| Simcere Pharmaceutical Group LtdCIK 0002082516 | Other: Former 10% Owner |
| Simcere Zaiming Pharmaceutical Co., Ltd.CIK 0002088064 | Other: Former 10% Owner |
| Tang RenhongCIK 0002088593 | Other: Former 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Common Stock | SSaleDisposed | −30,000 | $6.16 | −$184,800 | 308,636 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
This Form 4 constitutes an exit filing for the Reporting Persons, as they have ceased to be beneficial owners of more than 10% of the Issuer's common stock and therefore are no longer subject to Section 16 of the Exchange Act as a result of the sale described above.